

# COVID-19 und Diabetes – ein böses Paar

C. Steenblock, S. R. Bornstein

## Literatur

- [1] Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, Aung K, Mukherjee D and Dwivedi AK (2021) A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. *Sci Rep* 11:8562. doi: 10.1038/s41598-021-88130-w
- [2] Boucher J, Kleinridders A and Kahn CR (2014) Insulin receptor signaling in normal and insulin-resistant states. *Cold Spring Harb Perspect Biol* 6. doi: 10.1101/cshperspect.a009191
- [3] Esser N, Legrand-Poels S, Piette J, Scheen AJ and Paquot N (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. *Diabetes Res Clin Pract* 105:141-50. doi: 10.1016/j.diabres.2014.04.006
- [4] Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, Tkachuk VA, Markov AG, Lehnert H, de Angelis MH, Rietzsch H, Rodionov RN, Khunti K, Hopkins D, Birkenfeld AL, Boehm B, Holt RIG, Skyler JS, DeVries JH, Renard E, Eckel RH, Alberti K, Geloneze B, Chan JC, Mbanya JC, Onyegbutulem HC, Ramachandran A, Basit A, Hassanein M, Bewick G, Spinass GA, Beuschlein F, Landgraf R, Rubino F, Mingrone G and Bornstein SR (2021) COVID-19 and metabolic disease: mechanisms and clinical management. *Lancet Diabetes Endocrinol* 9:786-798. doi: 10.1016/S2213-8587(21)00244-8
- [5] Bornstein SR, Rubino F, Ludwig B, Rietzsch H, Schwarz PEH, Rodionov RN, Khunti K, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RIG, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Geloneze B, Chan JC, Mbanya JC, Onyegbutulem HC, Ramachandran A, Basit A, Hassanein M, Spinass GA, Beuschlein F and Mingrone G (2021) Consequences of the COVID-19 pandemic for patients with metabolic diseases. *Nat Metab* 3:289-292. doi: 10.1038/s42255-021-00358-y
- [6] Santos A, Magro DO, Evangelista-Poderoso R and Saad MJA (2021) Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. *Diabetol Metab Syndr* 13:23. doi: 10.1186/s13098-021-00639-2
- [7] Montefusco L, Ben Nasr M, D'Addio F, Loretelli C, Rossi A, Pastore I, Daniele G, Abdelsalam A, Maestroni A, Dell'Acqua M, Ippolito E, Assi E, Uselli V, Seelam AJ, Fiorina RM, Chebat E, Morpurgo P, Lunati ME, Bolla AM, Finzi G, Abdi R, Bonventre JV, Rusconi S, Riva A, Corradi D, Santus P, Nebuloni M, Folli F, Zuccotti GV, Galli M and Fiorina P (2021) Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. *Nat Metab*. doi: 10.1038/s42255-021-00407-6
- [8] Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y, Huang X, Guo J, Zhang BH and Li H (2020) Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metab* 31:1068-1077 e3. doi: 10.1016/j.cmet.2020.04.021

- [9] Klonoff DC, Messler JC, Umpierrez GE, Peng L, Booth R, Crowe J, Garrett V, McFarland R and Pasquel FJ (2021) Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis. *Diabetes Care* 44:578-585. doi: 10.2337/dc20-1857
- [10] Alsadhan I, Alruwashid S, Alhamad M, Alajmi S, Alshehri S, Alfadhli E and Ekhzaimy A (2020) Diabetic ketoacidosis precipitated by Coronavirus disease 2019 infection: Case series. *Curr Ther Res Clin Exp* 93:100609. doi: 10.1016/j.curtheres.2020.100609
- [11] Chee YJ, Ng SJH and Yeoh E (2020) Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. *Diabetes Res Clin Pract* 164:108166. doi: 10.1016/j.diabres.2020.108166
- [12] Goldman S, Pinhas-Hamiel O, Weinberg A, Auerbach A, German A, Haim A, Zung A, Brener A, Strich D, Azoulay E, Levy-Khademi F, Ludar H, Koren I, Rachmiel M, Yackobovitch-Gavan M, Zuckerman-Levin N, David O, Halloun R, Cahn R, Ben-Ari T, Yeshayahu Y, Landau Z, Phillip M and Lebenthal Y (2021) Alarming increase in ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the first wave of the COVID-19 pandemic in Israel. *Pediatr Diabetes*. doi: 10.1111/pedi.13296
- [13] Heaney AI, Griffin GD and Simon EL (2020) Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection. *Am J Emerg Med* 38:2491 e3-2491 e4. doi: 10.1016/j.ajem.2020.05.114
- [14] Hollstein T, Schulte DM, Schulz J, Gluck A, Ziegler AG, Bonifacio E, Wendorff M, Franke A, Schreiber S, Bornstein SR and Laudes M (2020) Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report. *Nat Metab* 2:1021-1024. doi: 10.1038/s42255-020-00281-8
- [15] Li J, Wang X, Chen J, Zuo X, Zhang H and Deng A (2020) COVID-19 infection may cause ketosis and ketoacidosis. *Diabetes Obes Metab* 22:1935-1941. doi: 10.1111/dom.14057
- [16] Naguib MN, Raymond JK and Vidmar AP (2021) New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19. *J Pediatr Endocrinol Metab* 34:147-150. doi: 10.1515/jpem-2020-0426
- [17] Trieu C, Sunil B, Ashraf AP, Cooper J, Yarbrough A, Pinninti S and Boppana S (2021) SARS-CoV-2 infection in hospitalized children with type 1 and type 2 diabetes. *J Clin Transl Endocrinol* 26:100271. doi: 10.1016/j.jcte.2021.100271
- [18] Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, Boehm B, Amiel S, Holt RI, Skyler JS, DeVries JH, Renard E, Eckel RH, Zimmet P, Alberti KG, Vidal J, Geloneze B, Chan JC, Ji L and Ludwig B (2020) Practical recommendations for the management of diabetes in patients with COVID-19. *Lancet Diabetes Endocrinol* 8:546-550. doi: 10.1016/S2213-8587(20)30152-2
- [19] Coate KC, Cha J, Shrestha S, Wang W, Goncalves LM, Almaca J, Kapp ME, Fasolino M, Morgan A, Dai C, Saunders DC, Bottino R, Aramandla R, Jenkins R, Stein R, Kaestner KH, Vahedi G, Consortium H, Brissova M and Powers AC (2020) SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in beta Cells. *Cell Metab* 32:1028-1040 e4. doi: 10.1016/j.cmet.2020.11.006
- [20] Kusmartseva I, Wu W, Syed F, Van Der Heide V, Jorgensen M, Joseph P, Tang X, Candelario-Jalil E, Yang C, Nick H, Harbert JL, Posgai AL, Paulsen JD, Lloyd R, Cechin S, Pugliese A, Campbell-Thompson M, Vander Heide RS, Evans-Molina C, Homann D and Atkinson MA (2020) Expression of SARS-CoV-2 Entry Factors in the Pancreas of Normal Organ Donors and Individuals with COVID-19. *Cell Metab* 32:1041-1051 e6. doi: 10.1016/j.cmet.2020.11.005

- [21] Liu F, Long X, Zhang B, Zhang W, Chen X and Zhang Z (2020) ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. *Clin Gastroenterol Hepatol* 18:2128-2130 e2. doi: 10.1016/j.cgh.2020.04.040
- [22] Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, Overbergh L, Gysemans C, Colli ML, Marchetti P, Mathieu C, Eizirik DL, Sebastiani G and Dotta F (2020) SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic beta-Cells and in the Human Pancreas Microvasculature. *Front Endocrinol (Lausanne)* 11:596898. doi: 10.3389/fendo.2020.596898
- [23] Muller JA, Gross R, Conzelmann C, Kruger J, Merle U, Steinhart J, Weil T, Koepke L, Bozzo CP, Read C, Fois G, Eiseler T, Gehrman J, van Vuuren J, Wessbecher IM, Frick M, Costa IG, Breunig M, Gruner B, Peters L, Schuster M, Liebau S, Seufferlein T, Stenger S, Stenzinger A, MacDonald PE, Kirchhoff F, Sparrer KMJ, Walther P, Lickert H, Barth TFE, Wagner M, Munch J, Heller S and Kleger A (2021) SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. *Nat Metab* 3:149-165. doi: 10.1038/s42255-021-00347-1
- [24] Wu CT, Lidsky PV, Xiao Y, Lee IT, Cheng R, Nakayama T, Jiang S, Demeter J, Bevacqua RJ, Chang CA, Whitener RL, Stalder AK, Zhu B, Chen H, Goltsev Y, Tzankov A, Nayak JV, Nolan GP, Matter MS, Andino R and Jackson PK (2021) SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment. *Cell Metab.* doi: 10.1016/j.cmet.2021.05.013
- [25] Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, Jarzebska N, von Massenhausen A, Linkermann A, Schurmann A, Pablik J, Dienemann T, Evert K, Rodionov RN, Semenova NY, Zinserling VA, Gainetdinov RR, Baretton G, Lindemann D, Solimena M, Ludwig B and Bornstein SR (2021) Viral infiltration of pancreatic islets in patients with COVID-19. *Nat Commun* 12:3534. doi: 10.1038/s41467-021-23886-3
- [26] Langouche L, Van den Berghe G and Gunst J (2021) Hyperglycemia and insulin resistance in COVID-19 versus non-COVID critical illness: Are they really different? *Critical Care* 25:437. doi: 10.1186/s13054-021-03861-6
- [27] Laurenzi A, Caretto A, Molinari C, Mercalli A, Melzi R, Nano R, Tresoldi C, Rovere Querini P, Ciceri F, Lampasona V, Bosi E, Scavini M and Piemonti L (2021) No evidence of long-term disruption of glycometabolic control after SARS-CoV-2 infection. *J Clin Endocrinol Metab.* doi: 10.1210/clinem/dgab792
- [28] Qadir MMF, Bhondeley M, Beatty W, Gaupp DD, Doyle-Meyers LA, Fischer T, Bandyopadhyay I, Blair RV, Bohm R, Rappaport J, Lazartigues E, Heide RSV, Kolls JK, Qin X and Mauvais-Jarvis F (2021) SARS-CoV-2 infection of the pancreas promotes thrombofibrosis and is associated with new-onset diabetes. *JCI Insight* 6. doi: 10.1172/jci.insight.151551
- [29] Zinserling VA, Bornstein SR, Narkevich TA, Sukhanova YV, Semenova NY, Vashukova MA and Steenblock C (2021) Stillborn child with diffuse SARS-CoV-2 viral infection of multiple organs. *IDCases* 26:e01328. doi: 10.1016/j.idcr.2021.e01328
- [30] Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, Pavkov ME, Rolka DB, Wiltz JL, Bull-Otterson L, Gray S, Boehmer TK, Gundlapalli AV, Siegel DA, Kompaniyets L, Goodman AB, Mahon BE, Tauxe RV, Remley K and Saydah S (2022) Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years - United States, March 1, 2020-June 28, 2021. *MMWR Morb Mortal Wkly Rep* 71:59-65. doi: 10.15585/mmwr.mm7102e2
- [31] Birabaharan M, Kaelber DC, Pettus JH and Smith DM Risk of new-onset type 2 diabetes in 600055 people after COVID-19: A cohort study. *Diabetes, Obesity and Metabolism* n/a. doi: 10.1111/dom.14659

- [32] Kamrath C, Monkemoller K, Biester T, Rohrer TR, Warncke K, Hammersen J and Holl RW (2020) Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. *JAMA* 324:801-804. doi: 10.1001/jama.2020.13445
- [33] Salmi H, Heinonen S, Hastbacka J, Laaperi M, Rautiainen P, Miettinen PJ, Vapalahti O, Hepojoki J and Knip M (2021) New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. *Arch Dis Child*. doi: 10.1136/archdischild-2020-321220
- [34] Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA and Buse JB (2021) COVID-19, Hyperglycemia, and New-Onset Diabetes. *Diabetes Care* 44:2645-2655. doi: 10.2337/dc21-1318
- [35] Maestre-Muniz MM, Arias A, Mata-Vazquez E, Martin-Toledano M, Lopez-Larramona G, Ruiz-Chicote AM, Nieto-Sandoval B and Lucendo AJ (2021) Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. *J Clin Med* 10. doi: 10.3390/jcm10132945
- [36] Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S, Ji L, Hopkins D, Herman WH, Khunti K, Mbanja JC and Renard E (2020) New-Onset Diabetes in Covid-19. *N Engl J Med* 383:789-790. doi: 10.1056/NEJMc2018688
- [37] Bornstein S (2022) Long-COVID und Diabetes. *Diabetes aktuell* 20:30-35.
- [38] Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Minambres I and Gomez-Huelgas R (2014) Glucocorticoid-induced hyperglycemia. *J Diabetes* 6:9-20. doi: 10.1111/1753-0407.12090
- [39] Chudasama YV, Gillies CL, Zaccardi F, Coles B, Davies MJ, Seidu S and Khunti K (2020) Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. *Diabetes Metab Syndr* 14:965-967. doi: 10.1016/j.dsx.2020.06.042
- [40] Rowlands AV, Henson JJ, Coull NA, Edwardson CL, Brady E, Hall A, Khunti K, Davies M and Yates T (2021) The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes. *Diabet Med* 38:e14549. doi: 10.1111/dme.14549
- [41] Cena H, Fiechtner L, Vincenti A, Magenes VC, De Giuseppe R, Manuelli M, Zuccotti GV and Calcaterra V (2021) COVID-19 Pandemic as Risk Factors for Excessive Weight Gain in Pediatrics: The Role of Changes in Nutrition Behavior. A Narrative Review. *Nutrients* 13. doi: 10.3390/nu13124255
- [42] Dun Y, Ripley-Gonzalez JW, Zhou N, You B, Li Q, Li H, Zhang W, Thomas RJ, Olson TP, Liu J, Dong Y and Liu S (2021) Weight gain in Chinese youth during a 4-month COVID-19 lockdown: a retrospective observational study. *BMJ Open* 11:e052451. doi: 10.1136/bmjopen-2021-052451
- [43] Kang HM, Jeong DC, Suh BK and Ahn MB (2021) The Impact of the Coronavirus Disease-2019 Pandemic on Childhood Obesity and Vitamin D Status. *J Korean Med Sci* 36:e21. doi: 10.3346/jkms.2021.36.e21
- [44] Gregg EW, Sophiea MK and Weldegiorgis M (2021) Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. *Diabetes Care*. doi: 10.2337/dci21-0001

- [45] McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, Hutchinson S, Caparrotta TM, Mellor J, Jeyam A, O'Reilly JE, Wild SH, Hatam S, Hohn A, Colombo M, Robertson C, Lone N, Murray J, Butterly E, Petrie J, Kennon B, McCrimmon R, Lindsay R, Pearson E, Sattar N, McKnight J, Philip S, Collier A, McMenemy J, Smith-Palmer A, Goldberg D, McKeigue PM, Colhoun HM, Public Health Scotland C-HPHG and Scottish Diabetes Research Network Epidemiology G (2021) Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. *Lancet Diabetes Endocrinol* 9:82-93. doi: 10.1016/S2213-8587(20)30405-8
- [46] Petrie JR, Boyle JG, Ali K, Smith C, Morrison D and Kar P (2021) A post COVID-19 'Marshall Plan' for type 2 diabetes. *Diabet Med* 38:e14439. doi: 10.1111/dme.14439
- [47] Ceriello A and Prattichizzo F (2021) Pharmacological management of COVID-19 in type 2 diabetes. *J Diabetes Complications* 35:107927. doi: 10.1016/j.jdiacomp.2021.107927
- [48] BBC (2020).
- [49] Dandona P and Ghanim H (2021) Diabetes, Obesity, COVID-19, Insulin, and Other Antidiabetes Drugs. *Diabetes Care*. doi: 10.2337/dci21-0003
- [50] Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R and Landray MJ (2020) Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. doi: 10.1056/NEJMoa2021436
- [51] Group WHOREAfC-TW, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Juni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Moller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S and Marshall JC (2020) Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* 324:1330-1341. doi: 10.1001/jama.2020.17023
- [52] Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Neshet L, Stein M, Maor Y, Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad H, Rahav G and Wiener-Well Y (2021) BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect*. doi: 10.1016/j.cmi.2021.06.036
- [53] Juthani PV, Gupta A, Borges KA, Price CC, Lee AI, Won CH and Chun HJ (2021) Hospitalisation among vaccine breakthrough COVID-19 infections. *Lancet Infect Dis* 21:1485-1486. doi: 10.1016/S1473-3099(21)00558-2
- [54] Marfella R, Sardu C, D'Onofrio N, Prattichizzo F, Scisciola L, Messina V, La Grotta R, Balestrieri ML, Maggi P, Napoli C, Ceriello A and Paolisso G (2022) Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. *Nat Commun* 13:2318. doi: 10.1038/s41467-022-30068-2